NEW YORK, May 28, 2020 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) today announced publication of a paper: The
Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute
Myeloid Leukemia with Activated Protein Kinase C by
Peter M. Alexander, Gregory L. Kucera, Kristin M. Pladna and Timothy S. Pardee in the July 2020 issue of Translational Oncology. The
paper documents the results from the company's sponsored research
at Wake Forest University.
The article reviews the approach to treating Acute Myeloid
Leukemia (AML), an aggressive malignancy with poor outcomes.
Nucleoside analogs are subject to resistance mechanisms including
downregulation of equilibrative nucleoside transporter (ENT1) and
deoxycytidine kinase (dCK). KPC34 is a novel phospholipid mimetic
that when cleaved by phospholipase C (PLC) liberates gemcitabine
monophosphate and a diacylglycerol mimetic that inhibits the
classical isoforms of protein kinase C (PKC). KPC34 acts
independently of ENT1 and dCK. KPC34 was active against all AML
cell lines tested with IC50s in the nanomolar range. Enforced
expression of PLC increased response to KPC34 in vivo. In an
orthotopic, xenograft model, KPC34 treatment resulted in a
significant increase in survival compared to control animals and
those treated with high-dose cytarabine. In a PDX model with
activated PKC, there was a significant survival benefit with KPC34,
and at progression, there was attenuation of PKC activation in the
resistant cells. In contrast, KPC34 was ineffective against a
syngeneic, orthotopic AML model without activated PKC. However,
when cells from that model were forced to express PKC, there were
significantly increased sensitivity in vitro and survival benefit
in vivo. These data suggest that KPC34 is active against AML and
that the presence of activated PKC can be a predictive
biomarker.
Anthony Hayes, CEO of AIkido
stated, "Wake Forest University is a
world-class research facility and an outstanding partner for
AIkido. This detailed research report helps to quantify the
expected benefits of our novel approach to this aggressive disease
with what we hope will be a transformative solution."
The published paper is available at
https://www.sciencedirect.com/science/article/pii/S1936523320300279
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-publication-of-results-from-sponsored-research-at-wake-forest-university-301067037.html
SOURCE AIkido Pharma Inc.